Recombinant Factor VIIa for Reversal of Warfarin Anticoagulation in Intracranial Hemorrhage
نویسندگان
چکیده
منابع مشابه
Use of recombinant factor VIIa for emergency reversal of anticoagulation.
CONTEXT There is limited data regarding the use of activated recombinant factor VII (rFVIIa) in anticoagulated patients requiring reversal. AIMS To identify and describe characteristics of subjects who received rFVIIa as part of emergency treatment aimed at improving hemostasis. SETTINGS AND DESIGN Data was obtained from an international peer-reviewed registry haemostasis.com. This registry...
متن کاملPoor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal.
BACKGROUND AND PURPOSE Anticoagulant-associated intracranial hemorrhage (aaICH) presents with larger hematoma volumes, higher risk of hematoma expansion, and worse outcome than spontaneous intracranial hemorrhage. Prothrombin complex concentrates (PCCs) are indicated for urgent reversal of anticoagulation after aaICH. Given the lack of randomized controlled trial evidence of efficacy, and the p...
متن کاملThromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case–control study
BACKGROUND Recombinant factor VIIa (rFVIIa) may be used for rapid hemostasis in life-threatening hemorrhage. In warfarin-associated intracerebral hemorrhage (wICH), FVIIa use is controversial and may carry significant thromboembolic risks. We compared incidence of baseline thromboembolic risk factors and thromboembolism rates in wICH patients treated with additional rFVIIa to those treated with...
متن کاملRecombinant factor VIIa use in patients presenting with intracranial hemorrhage
Recombinant factor VIIa (rFVIIa) can be used for rapid INR normalization in life-threatening hemorrhage in anticoagulated patients. Dosing is unclear and may carry thromboembolic risks. We reviewed the use of rFVIIa at a comprehensive stroke and cerebrovascular center to evaluate dose effectiveness on INR reduction and thromboembolic complications experienced. The primary endpoint was to review...
متن کاملComparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
INTRODUCTION Prothrombin complex concentrate (PCC) and recombinant Factor VIIa (rFVIIa) have been used for emergent reversal of warfarin anticoagulation. Few clinical studies have compared these agents in warfarin reversal. We compared warfarin reversal in patients who received either 3 factor PCC (PCC3) or low-dose rFVIIa (LDrFVIIa) for reversal of warfarin anticoagulation. METHODS Data were...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Surgery for Cerebral Stroke
سال: 2012
ISSN: 0914-5508,1880-4683
DOI: 10.2335/scs.40.14